Valuation: Opus Genetics, Inc.

Market Cap 304M 262M 247M 224M 422M 29.1B 428M 2.89B 1.13B 14.55B 1.14B 1.12B 48.47B P/E 2026 *
-3.69x
P/E 2027 * -5.18x
Enterprise Value 304M 262M 247M 224M 422M 29.1B 428M 2.89B 1.13B 14.55B 1.14B 1.12B 48.47B EV / Sales 2026 *
22.6x
EV / Sales 2027 * 21.1x
Free-Float
89.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+1.10%
1 week-4.90%
Current month-0.54%
1 month+20.98%
3 months-16.89%
6 months-1.60%
Current year+83.58%
1 week 3.55
Extreme 3.55
3.99
1 month 2.82
Extreme 2.82
3.99
Current year 1.88
Extreme 1.88
5.81
1 year 1.1
Extreme 1.1
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 2023-10-31
Director of Finance/CFO 52 2025-09-01
President 60 2024-10-21
Director TitleAgeSince
Director/Board Member 77 2020-10-31
Chairman 56 2019-11-30
Director/Board Member 59 2020-10-31
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Sell

Chief Financial Officer

-7,783 0.0094%
7/23/26 Sell

Chairperson

-7,429 0.0090%
7/23/26 Sell

Chief Executive Officer

-9,475 0.0115%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%-4.90%+220.87%-8.21% 304M
+3.60%+0.88%+75.59%+124.32% 1,055B
+3.33%+4.35%+53.82%+57.17% 632B
+3.43%+3.53%+25.34%+72.45% 442B
+1.35%-3.27%+40.98%+39.91% 351B
+1.75%-0.98%+26.20%+39.73% 290B
+2.13%-1.53%+1.85%+9.40% 243B
+1.41%+2.65%+45.34%+62.43% 227B
+1.35%-3.20%-9.07%-53.51% 200B
+3.25%+5.65%+21.57%+89.04% 172B
Average +2.23%-1.32%+50.25%+43.27% 361.28B
Weighted average by Cap. +2.78%-1.87%+44.19%+68.06%

Financials

2026 *2027 *
Net sales 13.44M 11.6M 10.92M 9.92M 18.66M 1.29B 18.94M 128M 50.19M 644M 50.44M 49.35M 2.14B 14.39M 12.43M 11.7M 10.63M 19.99M 1.38B 20.29M 137M 53.77M 690M 54.04M 52.87M 2.3B
Net income -92.68M -80.05M -75.31M -68.45M -129M -8.88B -131M -883M -346M -4.44B -348M -340M -14.79B -68.16M -58.87M -55.39M -50.34M -94.69M -6.53B -96.08M -650M -255M -3.27B -256M -250M -10.88B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
26-08-18 US$3.690 +1.10% 752,869
26-08-17 US$3.650 +1.11% 608,374
26-08-14 US$3.610 -2.96% 414,480
26-08-13 US$3.720 -1.06% 513,353
26-08-12 US$3.760 -3.09% 480,422
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
3.650USD
Average target price
10.61USD
Spread / Average Target
+190.72%

Quarterly revenue - Rate of surprise